Research graph
References from Single-cell transcriptomic characterization of a human MDS hematopoietic dataset and in vitro validation of apoptosis-related venetoclax resistance in human MDS-L cells. Local targets link to admitted publications; unresolved targets remain external evidence.
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
10.1016/s2352-3026(22)00216-2 · 2022 · External reference
Pathways and mechanisms of venetoclax resistance
10.1080/10428194.2017.1283032 · 2017 · External reference
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
10.3324/haematol.2020.260331 · 2022 · External reference
Myelodysplastic syndromes
10.1056/nejmra1904794 · 2020 · External reference
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020 · External reference
Ferroptosis: an iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · 2012 · External reference
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
10.1038/s41591-022-01696-4 · 2022 · External reference
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
10.1182/blood.2024025464 · 2025 · External reference
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
10.1002/ajh.26984 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Ferroptosis: mechanisms, biology and role in disease
10.1038/s41580-020-00324-8 · 2021 · External reference
Fast, sensitive and accurate integration of single-cell data with Harmony
10.1038/s41592-019-0619-0 · 2019 · External reference
Treatment of MDS
10.1182/blood-2018-10-844696 · 2019 · External reference
Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease
10.1016/j.cell.2017.09.021 · 2017 · External reference
Integrative single-cell analysis
10.1038/s41576-019-0093-7 · 2019 · External reference
Comprehensive integration of single-cell data
10.1016/j.cell.2019.05.031 · 2019 · External reference
Activation of RAS/MAPK pathway confers MCL-1-mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
10.1038/s41392-021-00870-3 · 2022 · External reference
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
10.1002/ajh.26984 · ExternalCitation · doi-reference
Ferroptosis: an iron-dependent form of nonapoptotic cell death
10.1016/j.cell.2012.03.042 · ExternalCitation · doi-reference
Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease
10.1016/j.cell.2017.09.021 · ExternalCitation · doi-reference
Comprehensive integration of single-cell data
10.1016/j.cell.2019.05.031 · ExternalCitation · doi-reference
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
10.1016/s2352-3026(22)00216-2 · ExternalCitation · doi-reference
Activation of RAS/MAPK pathway confers MCL-1-mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
10.1038/s41392-021-00870-3 · ExternalCitation · doi-reference
Integrative single-cell analysis
10.1038/s41576-019-0093-7 · ExternalCitation · doi-reference
Ferroptosis: mechanisms, biology and role in disease
10.1038/s41580-020-00324-8 · ExternalCitation · doi-reference
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
10.1038/s41591-022-01696-4 · ExternalCitation · doi-reference
Fast, sensitive and accurate integration of single-cell data with Harmony
10.1038/s41592-019-0619-0 · ExternalCitation · doi-reference
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · ExternalCitation · doi-reference
Myelodysplastic syndromes
10.1056/nejmra1904794 · ExternalCitation · doi-reference
Pathways and mechanisms of venetoclax resistance
10.1080/10428194.2017.1283032 · ExternalCitation · doi-reference
Treatment of MDS
10.1182/blood-2018-10-844696 · ExternalCitation · doi-reference
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
10.1182/blood.2024025464 · ExternalCitation · doi-reference
Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition
10.3324/haematol.2020.260331 · ExternalCitation · doi-reference
